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Background and aims: Despite the clinical importance of atherosclerosis, the origin of cells within
atherosclerotic plaques is not fully understood. Due to the lack of a deﬁnitive lineage-tracing strategy,
previous studies have provided controversial results about the origin of cells expressing smooth muscle
and macrophage markers in atherosclerosis. We here aim to identify the origin of vascular smooth
muscle (SM) cells and macrophages within atherosclerosis lesions.
Methods: We combined a genetic fate mapping approach with single cell expression analysis in a murine
model of atherosclerosis.
Results: We found that 16% of CD68-positive plaque macrophage-like cells were derived frommature SM
cells and not from myeloid sources, whereas 31% of aSMA-positive smooth muscle-like cells in plaques
were not SM-derived. Further analysis at the single cell level showed that SM-derived CD68þ cells
expressed higher levels of inﬂammatory markers such as cyclooxygenase 2 (Ptgs2, p ¼ 0.02), and vascular
cell adhesion molecule (Vcam1, p ¼ 0.05), as well as increased mRNA levels of genes related to matrix
synthesis such as Col1a2 (p ¼ 0.01) and Fn1 (p ¼ 0.04), than non SM-derived CD68þ cells.
Conclusions: These results demonstrate that smooth muscle cells within atherosclerotic lesions can
switch to a macrophage-like phenotype characterized by higher expression of inﬂammatory and syn-
thetic markers genes that may further contribute to plaque progression.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerosis, a chronic inﬂammatory disease of the arterial
wall, is one of the most common causes of death worldwide due to
the rupture of unstable plaques and associated acute thrombotic
events [14]. Key players in atherosclerosis development are lipid-
phagocytosing macrophages [11,15], but also dedifferentiated
vascular smooth muscle cells (VSMCs), which are believed to
migrate from the media to the intima, where they contribute to
the propagation of the inﬂammatory response [3]. However, VSMC
in the plaque may also have beneﬁcial roles, since lesions that are
prone to plaque rupture are associated with a reduced fraction of
VSMCs relative to macrophages [23]. A number of studies also
suggested that subgroups of VSMCs may transdifferentiate into
macrophages and thereby contribute to plaque developmentHeart and Lung Research,
. Albarran-Juarez).
Ireland Ltd. This is an open access[1,18], though these data remain controversial [22]. A current
limitation in the ﬁeld is that many of the markers used to identify
cell types within a plaque, such as the macrophage/monocyte
marker CD68 or smooth muscle (SM) cell marker SM a-actin
(Acta2, also known as aSMA), are up- or down-regulated during
cellular transdifferentiation and therefore only report the current
state of a given cell, not its origin [8]. Therefore there is a sub-
stantial ambiguity about the origin of smooth muscle- and
macrophage-positive marker cells within plaques contributing to
atherosclerosis progression. The only way to circumvent these
problems is the use of lineage tracing approaches in animals
genetically engineered to express speciﬁc permanent markers in
the cell population of interest. Using this technique in apolipo-
protein E deﬁcient mice (ApoE/), Feil et al. recently reported
that SM-derived cells in the plaque express macrophage markers
[7]. However, the low labelling efﬁciency in this study precluded a
quantitative assessment of the overall contribution of these cells
to atherosclerotic lesions [22]. Another recent lineage tracing
study showed that VSMCs within atherosclerotic plaques could
change phenotypes to become macrophage-like cells, therebyarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
J. Albarran-Juarez et al. / Atherosclerosis 251 (2016) 445e453446introducing a new way of plasticity of these cells [21]. We here
combined a lineage tracing approach in two different reporter
lines with a single cell expression analysis to deﬁne the proportion
and functional relevance of VSMC transdifferentiation in athero-
sclerotic plaque cells.
2. Materials and methods
2.1. Mice
The Animal Ethics Committees of Karlsruhe and Darmstadt
approved all mouse procedures (Protocol No. B2/1009). Generation
of transgenic mouse lines on the C57BL6/N background was
described previously: for smooth muscle myosin heavy chain
transgenic mice (SMMHC-CreERT2) [26] and for monocytes/mac-
rophages (LysM-Cre) [5]. These mice were bred on the ApoE-
deﬁcient mouse line [17] and then crossed with the double ﬂuo-
rescent reporter line Rosa26ﬂox-mT-stop-ﬂox-mG (Jackson Lab, Stock
007576) reported by Ref. [16]. Mice were housed under a 12 h light-
dark cycle with free access to food and water and under pathogen-
free conditions. Cre recombinase was activated in male mice at 6e8
weeks of age with intraperitoneal injections of tamoxifen (1 mg/
mouse, Sigma T5648), one per day for 5 consecutive days. Five days
after the last tamoxifen injection, mice were fed a high fat diet for
16 weeks to accelerate development of atherosclerotic lesions. Diet
contained 21% butter fat and 1.5% cholesterol (Ssniff® TD88137).
Animals were euthanized by CO2 under intraperitoneal anesthesia
of ketamine (120 mg/kg, Pﬁzer, Germany) and xylazine (16 mg/kg,
Bayer; Germany), and then perfused via the left ventricle with
phosphate-buffered saline (PBS).
2.2. Histological analyses
Upon sacriﬁce, aortic arch arteries were carefully dissected and
ﬁxed in cold 4% paraformaldehyde (PFA) for 1 h on ice. Following
ﬁxation, vessels were washed with cold PBS several times,
embedded in O.C.T. tissue freezing medium (Sakura®, The
Netherlands) and stored at 80 C before sectioning. For immu-
noﬂuorescence analyses, arteries were sectioned (10 mm) and ﬁxed
with ice-cold acetone for 10 min, O.C.T. tissue freezing mediumwas
subsequently removed from the sections by washing three times
(5 min each) with PBS. Slides were then blocked in 5% normal goat
serum (Thermo Fisher, PCN5000), in PBS with 0.1% Triton X-100
(Sigma, Munich; Germany) at room temperature for 30 min.
Blocked sections were probed overnight at 4 C in dark with the
following antibodies: rat anti-mouse CD68 (dilution 1:100; Serotec,
MCA195, clone FA-11), mouse anti-aSMA (dilution 1:100; Abcam,
ab125057-biotin, clone 1A4), and rabbit anti-mouse SMMHC
(dilution 1:100; Abcam, ab53219). After primary antibody incuba-
tion, sections were rinsed three times for 5 min with PBS and
incubated with appropriate secondary antibodies in dark for 1 h at
room temperature: streptavidin (Alexa Flour 647; S32357), goat
anti-rat IgG (Cy5 conjugate; A10525) or goat anti-rabbit IgG (Cy5
conjugate; A10523) from Life Technologies, (1:200 dilutions). Cell
nuclei were then labeled with DAPI (Invitrogen, D3571) for 10 min
in the dark (5 mg/ml dilution 1:1000). Sections were thoroughly
washedwith PBS, air dried andmounted with FluoroMount (Sigma,
F4680).
2.3. Confocal images acquisition and analysis
Images were acquired with a SP5 Leica (Mannheim, Germany)
confocal microscope. Sequential 1 mm optical sections wereacquired with a 40 oil immersion objective at 405 (DAPI), 488
(EGFP), 561 (Tomato) and 633 nm (immunostaining) wave-
lengths, and contrast was enhanced using Leica software. A series
of three to ﬁve z-stack images (z-wide) were acquired from each
microscope ﬁeld view from different regions of the lesion such as
shoulder, ﬁbrous cap and media. Examination of each plane of the
z-stack was processed, reconstructed and quantiﬁed using Fiji
software [19], using maximum intensity projections. Immuno-
ﬂuorescence staining was only quantiﬁed if single cell nuclei
(DAPI signal) were associated with either EGFP or Tomato signal.
Merged signals and split channels were performed to delineate
the signal at single cell resolution. Quantiﬁcation was based on
the analysis of 3 individual z-stacks per section, total of 5e6
sections per area or atherosclerotic lesion, 4e5 lesions per vessel
(n ¼ 6 mice per genotype).
2.4. Single cell suspension from peritoneal cavity, bone marrow and
blood
Resident peritoneal macrophages were isolated as previously
described [9] brieﬂy cells were collected by a peritoneal lavagewith
ice-cold PBS supplemented with 2 mM EDTA (Sigma). Cells were
spun down for 10 min at 400x g at 4 C and resuspended at 1 106/
ml in PBS with 2 mM EDTA and 1% BSA, pH 7,4. Bone marrow-
derived cells were collected by ﬂushing both femur and tibia with
ice-cold PBS with 2 mM EDTA and 1% BSA. Bone marrow was
resuspended in the same buffer and by using a 70 mm cell strainer a
single cell solution was obtained. 200 ml of heparinized blood were
incubated in 1 ml Red blood cell lysis buffer (Sigma) for 3 min at
room temperature. The lysed blood was centrifuged for 5 min at
350x g and the pelleted were resuspended in PBS with 2 mM EDTA
and 1% BSA at a concentration of 1  106/ml. Cells were then
stained for ﬂow cytometry.
2.5. Flow cytometry
The following mAbs from eBioscience (except where another
vendor is noted) were used for staining: PE-Cy7-conjugated mAbs
to CD45R/B220 (103221, BioLegend), CD8a (25-0081) and Ly6C
(128017, BioLegend); APC-conjugated mAbs to CD4 (17-0042-81)
and Ly6G (127613, BioLegend); eFluor450-conjugated mAbs to
CD45 (48-0451-80) and CD11b (48-0112-82) and PerCpCy5.5-
conjugated mAb to F4/80 (45-4801-82). Conjugated isotype-
matched control mAbs were obtained from eBioscience, Bio-
Legend and BD. Cells were acquired on a Canto II ﬂow cytometer
(BD, Biosciences) and analyses were performed using Diva software
(BD, Biosciences).
2.6. Microﬂuidic capture of single cell and gene expression analysis
Aortae were isolated and all connective tissue was carefully
removed under the microscope. Then, arteries were cut longitu-
dinally and opened facing upward. Aortic atherosclerotic plaques
were carefully collected from SM reporter mice (n ¼ 8) with
Dumont forceps (11251-35, F.S.T) and directly placed on digestion
mix containing: collagenase II (2 mg/ml), elastase-I (0.04 mg/ml)
and DNase1 (5 U/ml) at 37 C for 60 min while shaking (all from
Worthington). Digested plaques were ﬁltered through
40 mm mesh and washed with PBS. Cells were sorted by forward
and sideward scatter and loaded onto a microﬂuidic-C1 Single-
Cell Auto Prep System (Fluidigm) for RNA isolation and cDNA
ampliﬁcation. Quantitative PCR was performed on harvested
cDNA at single cell level using 96.96 Dynamic Array IFC with a
Fig. 1. Characterization of lineage tracingmodels. Double ﬂuorescent (Rosa26ﬂox-mT-stop-ﬂox-mG) reporter mice were crossed with atheroprone ApoE deﬁcient mice and two cell-speciﬁc
Cre transgenic lines: the tamoxifen-inducible SMMHC-CreERT2 line, to label vascular smooth muscle cells (SM reporter), and the constitutive LysM-Cre, to label monocytes-derived mac-
rophages (myeloid reporter). (A) Representative aortic sections from SM reporter mice treated with vehicle (no tamoxifen) and after tamoxifen treatment. (B) Representative immuno-
ﬂuorescence staining for SMMHC and CD68 in aortic sections from SM reporter mice ﬁve days after tamoxifen treatment. (C) Percentages of EGFP-positive cells that expressed SMMHC or
CD68 (left) and of SMMHC-positive cells that were EGFPþ (right) in themedia of SM reportermice. (D) Representative aortic image frommyeloid reportermice. (E) Representative staining
for SMMHC and CD68 in aortic sections frommyeloid reportermice. (F) Percentages of EGFP-positive cells that expressed SMMHCor CD68 (left) and of CD68-positive cells that were EGFPþ
(right) in the adventitia frommyeloid reporter mice. Error bars showmean ± s.e.m. Scale bars 50 mm. L: lumen;M:mediawall; A: Adventitia. Quantiﬁcationwas based on the analysis of 3
individual z-stacks per section, total of 5e6 sections per region of interest, 4e5 regions per vessel (n ¼ 6 mice per genotype).
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Fig. 2. Outline of the study and characterization of non SM-derived cells in the atherosclerotic media. (A) A schematic diagram showing the outline of the study. SM reporter mice
received adaily injection of tamoxifen forﬁvedays at the age of 6e8weeks. Arteries fromSMandmyeloid reporter lineswere analyzed at different timepoints: i) oneweek after tamoxifen
or vehicle treatment for basal analysis and ii) after 16 weeks of high fat diet (HFD). (B) Representative cross-sections of arteries from SM reporter mice at different time points: at basal
conditions in the absence ofHFD (top), after 16weeks ofHFD in areas devoid of atherosclerotic plaque (middle) and in areaswith atherosclerosis (bottom). (C, andD) Representative aortic
cross-sections from SM reporter mice after 16 weeks of HFD co-stained for smooth muscle myosin heavy chain (SMMHC) (C) and CD68 (D). White arrows on magniﬁcations indicate
Tomatoþ and SMMHCþ or Tomatoþ and CD68þ double positive cells in themedia, cyan arrows indicate Tomatoþ cells that do not express either SMMHC or CD68. (F) Percentages of EGFPþ
and Tomatoþ cells in the aortic media wall from SM reporter mice at different time points, as described in B. (G) Percentage of non-SM derived medial cells (Tomatoþ) that expressed
J. Albarran-Juarez et al. / Atherosclerosis 251 (2016) 445e453448
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low ROX (BioRad, Hercules, CA, USA) and Delta Gene primer as-
says. Only single cell cDNAs negative for lineage markers Cdh5,
CD4, CD8, or CD19 and positive for Htrp (Ct < 20) were included
into statistical analyses. Because C1 cDNA samples are potentially
contaminated with genomic DNA, intron-spanning primer design
was used for all genes. For EGFP no intron-spanning design was
possible and a weak background ampliﬁcation (Ct > 20) was
observed even in the absence of Cre, most likely due to genomic
DNA ampliﬁcation. For EGFP analysis therefore only cells with
Ct < 20 (genomic background) were evaluated. The limit of
detection for the BioMark HD System has been estimated to be at
a Ct value of 24 cycles (Limit of detection (LoD) Ct); all sample Ct
values were therefore subtracted from the (LoD) Ct using the
formula: gene expression ¼ 2(Limit of Detection(LoD) Ct e measured Ct), as
previously described [12]. Primers used for single-cell RT-PCR are
listed in Supplementary Table 1.
2.7. Statistical analysis
All results are presented asmean ± s.e.m. Statistical analysis was
performed using GraphPad Prism 5 software (San Diego, USA).
Statistical comparison of two groups was performed using 2-tailed
Student’s t-test with p-values 0.05 considered statistically sig-
niﬁcant. “n” refers to the number of independent experiments or
mice per group.
3. Experimental results
To speciﬁcally label and lineage trace cells contributing to the
development of atherosclerotic lesions, we crossed
atherosclerosis-prone ApoE/ mice with a double ﬂuorescent
(Rosa26ﬂox-mT-stop-ﬂox-mG) reporter mouse and two different cell
type speciﬁc Cre lines: the tamoxifen-inducible SMMHC-CreERT2
line for VSMCs (SM reporter) and the constitutive LysM-Cre line
for neutrophils and monocyte-derived macrophages (myeloid
reporter) (Fig. 1A,D). In this reporter strain, the red ﬂuorescent
protein tomato is ubiquitously expressed at baseline and switches
to enhanced green ﬂuorescent protein (EGFPþ) in all cells that
have undergone Cre-mediated recombination as well as their
progeny.
Five days after the last tamoxifen injection aortic sections from
SM reporter mice showed a homogeneous EGFPþ expression in the
media wall, but not in the adventitia or the endothelial layer
(Fig. 1A). Immunostaining with antibodies to smooth muscle
marker myosin heavy chain (SMMHC) and macrophage/monocyte
marker CD68 showed that 98% of EGFPþ cells were SMMHC-
positive, and that 96% of SMMHCþ cells expressed EGFP. Further-
more, we did not detect EGFP expression in CD68þ cells (Fig. 1B,C).
In addition, ﬂow cytometry analyses of various leukocyte pop-
ulations from blood or bonemarrow from SM reporter mice did not
show signiﬁcant EGFPþ expression (Supplementary Table 2). These
data show that SM reporter mice speciﬁcally labeled mature
differentiated VSMCs.
As lysozyme M promoter activity in myeloid reporter mice is
maturation stage-dependent [6], we evaluated the degree of
recombination in aortae from myeloid reporter mice at the steady
stage. In aortic sections of myeloid reporter mice, EGFPþ
expression was restricted to the adventitia (Fig. 1D). In detail, 96%SMMHCorCD68markers. (H) Representative confocal image showing EGFPexpression in athero
plaque,media and adventitia frommyeloid reportermice. Errorbars showmean± s.e.m. Scale ba
media wall; P: plaque; A: Adventitia. Quantiﬁcationwas based on the analysis of 3 individual z-
vessel (n ¼ 6 mice per genotype).of EGFP-expressing cells were CD68-positive cells, but none were
SMMHC-positive (Fig. 1E,F). Among the CD68þ cells of the
adventitia, 92% were EGFP positive (Fig. 1F). Flow cytometry
analysis showed that recombination in other myeloid populations
varied depending on the maturation stage between 30 and 98%,
while expression in lymphocytes was negligible (Supplementary
Table 2).
To study the origin of atherosclerotic plaque cells both mouse
lines were kept for 16 weeks on a western style high fat diet (HFD)
and then atherosclerotic aortae were subjected to immunohisto-
chemical analyses (Fig. 2A). Furthermore, single cell gene expres-
sion analyses were performed with atherosclerotic plaque cells
from SM reporter mice.
Analysis of vessels of the SM reporter line showed that in the
absence of HFD treatment as well as in plaque-free vessel regions of
HFD-treated mice, almost all cells in the media wall were EGFP-
positive, i.e., mature smooth muscle cells or derivatives thereof
(Fig. 2B, top andmiddle, 2F). Interestingly, in media regions directly
underlying atherosclerotic plaques an increased proportion of
EGFP-negative, non SM-derived cells, was observed (Fig. 2B, bot-
tom, 2F). 61% of these non-SM-derived medial cells were SMMHC-
positive (Fig. 2C,G), while 35% expressed CD68 (Fig. 2D,G) or neither
marker. To determine whether these non SM-derived cells were of
myeloid origin, we evaluated EGFP expression in the media of
myeloid reporter mice (Fig. 2H). We did not detect any myeloid-
derived cells in the plaque-adjacent media of myeloid reporter
mice (Fig. 2H,I), indicating that these EGFP-negative cells that we
observed in the media of SM reporter mice are not derived from
aortal macrophages and do not express LysM. We therefore
conclude that cell populations other than SM-derived cells or LysM-
positive cells contribute to remodeling processes in the athero-
sclerotic media.
We then investigated the origin of aSMAþ smooth muscle-like
cells within the plaque. It is in this context interesting to note
that in SM reporter mice more than 70% of EGFPþ (SM-derived)
cells within plaques had lost their aSMA expression, indicating a
massive dedifferentiation (Fig. 3A). While aSMA-negative SM-
derived cells were mainly localized in central plaque areas,
aSMAþ SM-derived cells were mostly found in the ﬁbrous cap
(Fig. 3A), where they have been shown to form an atheropro-
tective layer associated with plaque stability [10,24]. Our data
show that the majority of aSMAþ cells found in plaques were
EGFPþ and therefore SM-derived. Interestingly, approximately
31% of aSMAþ cells in plaques were EGFP-negative, showing that
non SM-derived cells up-regulate aSMA under atherosclerotic
conditions (Fig. 3A,C). Indeed, in atherosclerotic plaques from
myeloid reporter mice 17% of aSMAþ cells co-expressed EGFP,
indicating they were myeloid cell-derived (Fig. 3B,C). To investi-
gate whether SM-derived and non-SM-derived aSMA-positive
cells show functional differences, we performed single cell
expression analyses of atherosclerotic plaque cells from SM re-
porter mice. We found that SM-derived aSMAþ plaque cells
tended not only to express higher mRNA levels for SM differen-
tiation markers such as aSMA (Acta2), transgelin (Tagln) or
smoothelin (Smtn) than non SM-derived aSMAþ cells (Fig. 3D),
but also to express more pro-inﬂammatory marker genes and
growth factors such as cyclooxygenase 2 (Ptgs2), chemokine
ligand 10 (Cxcl10), vascular cell adhesion molecule (Vcam1), or
isoforms of transforming growth factor b (Tgfb) (Fig. 3E).sclerotic lesions frommyeloid reportermice. (I) Percentages of EGFP-positive cells in aortic
r: 50mm.Boxed regions are shownathighermagniﬁcation (scale bar: 25mm). L: lumen;M:
stacks per section, total of 5e6 sections per area or atherosclerotic lesion, 4e5 lesions per
Fig. 3. Lineage tracing and expression proﬁle of smooth muscle positive-marker cells in atherosclerotic plaques. (A and B) show representative images of aSMA-stained aortic
sections from SM reporter mice (A) and myeloid reporter mice (B). Boxed regions show higher magniﬁcations, white arrows indicate EGFPþ cells that were aSMAþwhile yellow arrows
showTomatoþ cells thatwereaSMAþ. (C) PercentagesofaSMAþ cells thatwereEGFPþ orTomatoþ in atheroscleroticplaques fromSMandmyeloid reportermice. (DandE)Geneexpression
proﬁle of EGFP-positive (SM-derived) and EGFP-negative (non SM-derived) Acta2þ cells in atherosclerotic plaques from SM reportermice. Expression data are calculated as follows: gene
expression¼ 2(Limit of Detection(LoD) Ctemeasured Ct), LoDCtwas set to 24. Error bars showmean± s.e.m.Comparisonsbetweengroupswereperformedusing2-tailed t-test. *,p 0.05. Scale bar:
50 mm. Boxed regions scale bar: 25 mm. L: lumen;M:mediawall; P: plaque; A: Adventitia. Quantiﬁcation of immunostainingswas basedon the analysis of 3 individual z-stacks per section,
total of 5e6 sections per atherosclerotic lesion, 4e5 lesions per vessel (n¼ 6mice per genotype). For single cell analysis, aortic atherosclerotic plaquewas pooled together fromvessels of 8
SM reporter mice.
Fig. 4. Lineage tracing and expression proﬁle of macrophage positive-marker cells in atherosclerotic plaques. (A and B) show representative immunoﬂuorescence staining for
CD68 in aortic atherosclerotic lesions from SM reporter mice (A) and from myeloid reporter mice (B). Boxed regions show higher magniﬁcations, white arrows indicate EGFPþ cells
that were CD68þwhile yellow arrows show Tomatoþ cells that were CD68þ. (C) Percentages of total CD68þ cells that were EGFPþ or Tomatoþ in atherosclerotic plaques from SM and
myeloid reporter lines. (D and E) Gene expression proﬁles of EGFP-positive (SM-derived) and EGFP-negative (non SM-derived) CD68þ cells in plaques from SM reporter mice.
Expression data are calculated as follows: gene expression ¼ 2(Limit of Detection(LoD) Ct e measured Ct), LoD Ct was set to 24. Error bars show mean ± s.e.m. Comparisons between groups
were performed using 2-tailed t-test. *, p  0.05; **, p  0.01. Scale bars 50 mm. Boxed regions are shown at higher magniﬁcation (scale bar: 25 mm). HFD: high fat diet; L: lumen; M:
media wall; P: plaque. Quantiﬁcation of immunostainings was based on the analysis of 3 individual z-stacks per section, total of 5e6 sections per atherosclerotic lesion, 4e5 lesions
per vessel (n ¼ 6 mice per genotype). For single cell analysis, aortic atherosclerotic plaque was pooled together from vessels of 8 SM reporter mice.
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atherosclerotic plaques, we used CD68 staining. Much to our sur-
prise we found in the SM reporter mice that 16% of CD68þ cells
within plaques were EGFPþ and therefore originated from medial
smooth muscle cells rather than from myeloid cells (Fig. 4A,C). In
atherosclerotic plaques from myeloid reporter mice, 60% of CD68þ
cells were EGFP-positive and therefore most likely myeloid-derived
macrophages or CD68þ neutrophils [2] (Fig. 4B,C). 40% of CD68þ
cells were EGFP-negative indicating that they were non myeloid-
derived. To further characterize the differences between non SM-
derived CD68þ cells (Tomatoþ/CD68þ) and SM-derived CD68þ
cells (EGFPþ/CD68þ), we again performed single cell expression
analysis by RT-PCR. We found that SM-derived CD68þ cells (EGFPþ/
CD68þ) expressed not only higher levels of smooth muscle marker
genes Acta2, Smtn, and Tagln, but also showed increased expression
of various pro-inﬂammatory markers (Fig. 4D). In addition, they
showed increased mRNA levels of genes related to matrix synthesis
and remodeling as well as growth factors (Fig. 4E). The only gene
that showed a trend to higher expression in non-SM-derived cells
was IL10, a cytokinewith known anti-inﬂammatory properties [13].
These ﬁndings suggest that SM-derived CD68þ cells more strongly
upregulate genes related tomatrix remodeling and inﬂammation in
plaques than their non SM-derived counterparts.
4. Discussion
In this study we provide a quantitative analysis of VSMCs
transdifferentiation in murine atherosclerotic plaques and describe
the transcriptional differences between SM-derived and non SM-
derived cell types. Much uncertainty in the ﬁeld is due to the use
of immunohistochemical markers for VSMCs that are well suited to
report the current state of a given cell, but not its origin [8]. Typical
markers of SM differentiation such as aSMA or transgelin, for
example, are rapidly down-regulated upon smooth muscle dedif-
ferentiation [25]; in line with this we found that 70% of SM-derived
plaque cells had lost their aSMA expression. Furthermore, aSMA
was up-regulated in various non SM-derived cells, for example in
17% of myeloid-derived cells. Similar observations were made in Y
chromosome lineage tracing studies in humans who had under-
gone cross-gender bone marrow transplantation where myeloid-
derived cells express aSMA in advanced coronary artery lesions
[4]. Based on these data we conclude that the presence or absence
of SM markers such as aSMA does not allow to draw conclusions
about the origin of a given plaque cell.
One of the major unresolved questions in the ﬁeld is whether
plaque macrophages can give rise non-myeloid precursor cells, and
if so, how these cells can be distinguish from their myeloid-derived
counterparts [22]. Our lineage-tracing experiments in myeloid re-
porter mice showed that 40% of all CD68-positive plaque cells were
EGFP-negative, indicating that the LysM promoter was never active
in these cells. The activity of the LysM promoter in myeloid cells is
known to be maturation stage-dependent [5,6], and our own ana-
lyses indicated that fully mature macrophages show recombination
frequencies of 95e98% in the myeloid reporter line. We therefore
hypothesize that these 40% EGFP-negative, CD68-positive cells in
the myeloid reporter are largely, though maybe not exclusively,
derived from other than myeloid cell populations. Potential can-
didates for this population are for example speciﬁc dendritic cells
subsets, which have been shown to express CD68, but not LysM
[20]. In addition, our analyses in SM reporter mice provide clear
evidence for a role of VSMC transdifferentiation [1,7,21]: 16% of
CD68þ cells in plaques are not of myeloid origin, but are SM-derived
cells. Our single cell expression analysis data also clearly show that
up-regulation of CD68 is not the only feature of SM to macrophage
transdifferentiation, since SM-derived CD68-positive cellsexpressed similar levels of leukocyte and macrophage markers
such as CD45 (Ptprc) and CD11b (Itgam) as their non SM-derived
counterparts. Interestingly, SM-derived CD68þ cells expressed
higher mRNA levels of pro-inﬂammatory and matrix synthesis/
remodeling genes than CD68þ cells of myeloid origin, suggesting
they represent a more aggressive population of plaque
macrophages.
Taken together, our results illustrate that VSMCs and macro-
phages within atherosclerotic lesions possess a high degree of
plasticity with regard to the expression of markers of other cell
lineages. This suggests a considerable amount of trans-
differentiation occurs in vivo, both from mature smooth muscle
cells to macrophage-like cells and from myeloid cells to smooth
muscle-like cells.
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